AzTrials
AzTrials

Clinical DeteriorationCOCOMONCT04189653

Clinical Outcomes After Implementation of COntinuous Vital Sign Monitoring On the General Ward.

An observational study of Clinical Deterioration, run by Radboud University Medical Center at 1 site in Netherlands.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In 2018, continuous monitoring (CM) of 5 vital signs with a wearable device, including automated MEWS calculation within the EMR were introduced on the surgical and internal medicine ward of our hospital. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Clinical Deterioration
What is being tested?
Continuous Monitoring
How many people
3,896 participants
Where
1 siteNetherlands
Study dates
1 Aug 2018to 1 Aug 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult general ward patients of the GE-surgery and Internal Medicine wards of a Dutch tertiary academic hospital.

Who may be able to join

  • Admission on Inclusion ward.

Who cannot join

  • Opt out of file study

Trial locations and contacts

1 site in 1 country.

Netherlands1 site
  • Radboudumc

    Nijmegen, Gelderland, 6525GA

Other trials in Netherlands

About this study

Official title: Clinical Outcomes After Implementation of Continuous Vital Sign Monitoring on the General Ward.

In 2018, continuous monitoring (CM) of 5 vital signs with a wearable device, including automated MEWS calculation within the EMR were introduced on the surgical and internal medicine ward of our hospital. Rather than taking the measurements manually, this enabled the nurses to periodically validate the continuously derived vital signs at the protocolled moments, and simultaneously get an automatically calculated MEWS reading,. Moreover, continuous vital sign monitoring provides single channel alarms and trends of the vital signs in between the regular measurement moments. Compared to periodic manual measurements and registration in the EMR, the continuous vital sign monitoring and automated MEWS calculations in the EMR may result in better identification of clinical deterioration, and may improve clinical outcome.

The primary objective of this study is to evaluate changes in total hospital and ward stay, "Total Events" during admission (rapid response team (RRT) calls and unexpected intensive care unit (uICU) admissions and deaths) after implementation of CM on the regular surgical and internal medicine wards. Secondary objective is to evaluate changes in MEWS scores at the moment of the uICU admissions, length of hospital, ward and ICU stay and the proportion of RRT calls that results in a ICU admission.

Being tested
Continuous Monitoring
Keywords
Early Warning Scores, Continuous Vital Sign Monitoring, Escalation of Care, ICU-Transfer, Deterioration prevention
Medical subject headings
Clinical Deterioration

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Continuous MonitoringOther

    Wireless continuous vital sign monitoring (HR, RR, SBP/DBP, SAT)

Study groups in NCT04189653
Study groupRoleWhat they receive
General Ward Inpatients 2017-2018ALL General Ward Inpatients on our Gastro-Enterology Surgery ward and Internal Medicine ward in the period august 1st 2017-august 31st 2018.
General Ward Inpatients 2018-2019ALL General Ward Inpatients on our Gastro-Enterology Surgery ward and Internal Medicine ward in the period august 1st 2018-august 31st 2019.
Receives: Other: Continuous Monitoring

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Unexpected Intensive Care Unit Admissions

    Unexpected Intensive Care Unit Admissions

    Measured: During ward admission, from moment of arival on ward till discharge or transfer, average of 4 days.

  2. Rapid Response Team Activations

    Rapid Response Team Activations

    Measured: During ward admission, from moment of arival on ward till discharge or transfer, average of 4 days.

Secondary outcomes (1)
  1. Length of Stay

    Length of stay on the ward, ICU and Hospital stay as whole

    Measured: During ward, ICU and hospital admission, till discharge, transfer to other hospital or death. Average of 5 days.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Dec 2019
  2. Study start1 Aug 2018
  3. Primary completion1 Aug 2019
  4. Study completion1 Aug 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
3,896 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04189653
Sponsor's protocol ID
2018-4330
Acronym
COCOMO
Status last verified
Nov 2019
First submitted
4 Dec 2019
Last updated
7 Sep 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Clinical Deterioration, run by Radboud University Medical Center at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Unexpected Intensive Care Unit Admissions (time frame: During ward admission, from moment of arival on ward till discharge or transfer, average of 4 days.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Sep 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in